ArticleAmerican journal of translational research2019
Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials.Acta diabetologica · 2026Pooled it
- If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?RMD open · 2025Trial
- Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.Gut microbes · 2026Review
- The Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review.Molecular neurobiology · 2026Review
- Pathological mechanisms of osteoarthritis in the network of geriatric comorbidities: Emerging insights from organs-crosstalk.Journal of orthopaedic translation · 2026Review
- Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine.Bone research · 2026Review
- GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026Review
- GLP-1 and GIP: Magic bullet for musculoskeletal diseases?Journal of advanced research · 2026Review
- Peptide-based targeted drug delivery strategies for osteoarthritis treatment.npj biomedical innovations · 2026Review
- Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis.Journal of nanobiotechnology · 2026Article
- The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.Nature reviews. Rheumatology · 2026Review
- Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.Frontiers in immunology · 2026Review
- The incretin-joint axis: weight-independent mechanisms and disease-modifying potential in chronic arthropathies.Rheumatology advances in practice · 2026Review
- Article
- Intertwined roles of microRNA-155 and metformin in osteoarthritis: Novel potential diagnostic, prognostic, and therapeutic modulators.World journal of orthopedics · 2025Review
- The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.Nature reviews. Rheumatology · 2025Review
- The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care.Current reviews in musculoskeletal medicine · 2025Review
- GLP-1 agonists: a game changer in pain treatment and addiction.Pain management · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a major global health problem; however, the etiology of the disease remains unknown and a reliable treatment strategy has yet to be discovered. Modulation of the receptor for glucagon-like peptide 1 (GLP-1) has emerged as a potential treatment strategy for various diseases including OA. In the present study, we investigated the effects of the specific GLP-1 receptor agonist liraglutide on factors of the pathogenesis of OA induced by tumor necrosis factor-α (TNF-α), including oxidative stress, expression of proinflammatory cytokines, degradation of articular cartilage extracellular matrix, and activation of the nuclear factor-κB (NF-κB) pathway. Our findings demonstrate that liraglutide exerted a potent beneficial effect in human primary chondrocytes by downregulating generation of reactive oxygen species and NADPH oxidase 4, suppressing expression of interleukin-6 and monocyte chemoattractant protein 1, rescuing type II collagen and aggrecan from degradation my matrix metalloproteinases and a disintegrin and metalloproteinase with type I thrombospondin motif, and inhibiting activation of the proinflammatory NF-κB signaling pathway. These findings demonstrate a potential role of GLP-1 receptor in the pathogenesis of OA and lay a foundation for further research on the mechanisms behind the potential therapeutic application of liraglutide in the treatment and prevention of OA.
Indexed as
Identifiers
31497200PMC6731440W2991033017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.